Neurodevelopmental disorders (NDs) encompass a spectrum of neuropsychiatric manifestations. Chromosomal regions 1q21.1, 3q29, 15q11.2, 15q13.3, 16p11.2, 16p13.1 and 22q11 harbour rare but recurrent CNVs that have been uncovered as being important risk factors for several of these disorders. These rearrangements may underlie a broad phenotypical spectrum, ranging from normal development, to learning problems, intellectual disability (ID), epilepsy and psychiatric diseases, such as autism spectrum disorders (ASDs) and schizophrenia (SZ). The highly increased risk of developing neurodevelopmental phenotypes associated with some of these CNVs makes them an unavoidable element in the clinical context in paediatrics, neurology and psychiatry. However, and although finding these risk loci has been the goal of neuropsychiatric genetics for many years, the translation of this recent knowledge into clinical practice has not been trivial. In this article, we will: (1) review the state of the art on recurrent CNVs associated with NDs, namely ASD, ID, epilepsy and SZ; (2) discuss the models used to dissect the underlying neurobiology of disease, (3) discuss how this knowledge can be used in clinical practice.
INTRODUCTION
Neurodevelopmental disorders (NDs) are a large group of clinical entities encompassing a spectrum of neuropsychiatric manifestations caused by disruption of brain development, including autism spectrum disorders (ASD), intellectual disability (ID), communication disorders, attention deficit and hyperactivity disorder (ADHD), specific learning disorders and motor disorders.
1 Schizophrenia (SZ) has also been proposed to result from neurodevelopmental disturbances, usually manifesting only in the adult stage. 2 The majority of NDs do not fit the Mendelian disease model where one gene is responsible for a given trait. 3 Most of them are polygenic or multifactorial and their clustering in families is believed to be influenced by genetic and environmental factors. 4 Two contrasting hypotheses have been advanced to explain the nature of this complexity: the common variant common disease (CVCD) and the rare variant common disease (RVCD) models. 5 According to the CVCD model, the genetic risk in an individual is attributable to many high frequency variants, each one having a modest effect on risk. In contrast, the RVCD model states that genetic risk in a given individual can be explained by rare mutations that confer significant risk. 5 6 Most likely, both types of contribution are important; the narrow-sense heritability in autism is ∼52.4%, most being due to common variants. 7 Rare CNVs-DNA segments larger than 1 Kb that present a copy number different from that of the reference genome 8 -contribute to a substantial proportion of the genetic variability in humans 9 but can also contribute for risk of developing a neurodevelopmental disturbance. Its association with a range of NDs 5 10 was only possible because advancements in chromosomal microarray (CMA) technology have allowed for CNV analysis in very large case-control cohorts. 11 A significant proportion of risk for ID, ASD, SZ, epilepsy, bipolar disease (BD) and ADHD can be explained by these rare variants. [12] [13] [14] [15] [16] [17] [18] [19] [20] The estimated risk, or OR, for most common disease-associated single nucleotide polymorphisms will be of-at most-up to 2 (with many between 1.1 and 1.4); in contrast, many-if not most-rare variants have been associated with ORs greater than 2, in some cases considerably larger. 6 Most of the experiments to study the impact of CNVs in dosage-sensitive gene expression in normal brain development have used lymphoblastoid cell lines, suggesting a functional impact of CNVs via transcriptome alterations. [21] [22] [23] Two studies on postmortem brain samples have shown that 1q21.1 and 22q11.2 CNVs influence gene expression in the dorsolateral prefrontal cortex; 24 25 interestingly, a significant proportion of CNVs influencing gene expression in the human prefrontal cortex were located in chromosomal regions implicated in psychiatric disorders, namely those in 1q21.1, 3q29, 15q11.2, 16p11.2, 16p13.1, 17q12 and 22q11.2. 25 Most recurrent pathogenic CNVs are large (>400 kb), typically involving dozens of genes, and are individually rare (frequency <0.1%). 11 Their discovery emphasised the importance of de novo and essentially private mutations in NDs, and indicated that the distinction between milder neuropsychiatric conditions and severe developmental impairment may be a consequence of increased mutational burden affecting multiple genes in the latter case. 3 Although finding such risk loci has been the goal of neuropsychiatric genetics for many years, the translation of this recent knowledge into clinical practice has not been trivial. In this article, we will: (1) review the state of the art on recurrent CNVs associated with NDs, namely ASD, ID, epilepsy and SZ; (2) discuss the models used to dissect the underlying mechanism of disease, (3) discuss how this knowledge can be used in clinical practice.
15q11.2 (BP1-BP2) deletions
The 15q11.2 (BP1-BP2) microdeletions (15q11.2del) range from 253 Kb to 1.5 Mb and have been associated with ID, SZ, DD and ASD, as well as with epilepsy (table 3) . 33 36 38 In fact, the combined frequency of this CNV along with 15q13.3del and 16p13.11del is approximately 3% in patients with genetic generalised epilepsy (GGE), 66 and these CNVs are particularly enriched in patients with ID plus GGE when compared with individuals with GGE or ID alone. 14 67 In spite of its location in the Prader-Willi/Angelman syndrome region, it does not contain the critical genes for these syndromes. This CNV encompasses four non-imprinted genes (figure 3): NIPA1, NIPA2, CYFIP1 and TUBGCP5. 36 38 Three of them are implicated in CNS development and/or function: NIPA1 and NIPA2 are widely expressed in neuronal tissues and CNS and mediate magnesium (Mg 2+ ) transport; 68 69 when mutated, they cause autosomal dominant hereditary spastic paraplegia 70 and childhood absence epilepsy, 71 respectively. CYFIP1 is expressed in the brain and encodes a protein that interacts with fragile X mental retardation protein (FMRP), the protein product of the fragile X syndrome gene. 72 FMRP and CYFIP1 play an important role in the regulation of mRNAs in brain, 73 and CYFIP1 is critical for the maintenance of dendritic complexity and the stabilisation of mature spines; dysregulation of CYFIP1 expression levels leads to pathological changes in CNS maturation and neuronal connectivity, which may contribute to the development of neuropsychiatric illness. 74 Finally, TUBGCP5 encodes a widely expressed core component of the gamma tubulin complex, required for microtubule nucleation at the centrosome. 
15q13.3 (BP4-BP5) rearrangements
Sharp and colleagues first described patients with ID, epilepsy and variable facial and digital dysmorphisms due to a 1.5-Mb deletion at 15q13.3 (15q13.3del), comprising the BP4-BP5 region (figure 3). 76 Patients with reciprocal duplications and a patient with a homozygous deletion and a severe phenotype including epileptic encephalopathy and autistic features were also observed. 77 78 This deletion is strongly associated with ID (OR >29.6) 27 and with SZ and related psychoses, [28] [29] [30] [31] while the reciprocal duplications seem to predispose to ADHD (table 4) . 20 The 15q13.3del was also recognised as a major risk factor (OR >50) for idiopathic generalised epilepsies (IGE). 39 In addition to this variable expressivity, incomplete penetrance (ie, healthy individuals presenting these deletions) has been observed, 33 40 probably due to additional genetic abnormalities, epigenetic factors and/or modifier genes and CNVs. 79 The critical region of 15q13.3del harbours at least seven genes (ARHGAP11B, FAN1/MTMR15, MTMR10, TRPM1, KLF13, OTUD7A and CHRNA7), but CHRNA7 soon emerged as a prime candidate gene responsible for some of the clinical findings associated with these CNVs, such as seizures, because of the identification of individuals with deletions containing only this gene. 80 CHRNA7 encodes the cholinergic receptor alpha 7 (neuronal), which belongs to the nicotinic acetylcholine receptor (nAChRs) superfamily of ligand-gated ion channels that mediate signal transmission at synapses. It plays roles in central and peripheral nervous system development, cognitive performance and inflammation; 81 it is highly expressed in the reticular thalamus, indicating a role in modulating thalamocortical pathways, which are central to the generation of primary generalised seizures seen in IGE. Indirect evidence for its role in epileptogenesis comes from the fact that mutations in other nAChR family members cause autosomal dominant nocturnal frontal lobe epilepsy. 39 40 Nevertheless, no patients with point mutations in CHRNA7 gene were described until now: 62 82 only some non-coding variants associated with reduced gene expression have been found in one patient with ASD 83 as well as in patients with SZ. 81 The a7nAChR is also a relevant pharmacological target, as agonists of nAChRs are currently being considered in the treatment of NDs. [84] [85] [86] In a maternal immune activation (MIA) mouse model, a murine model of environmental risk factors for autism and SZ, it was shown that this receptor modulates the inflammatory response after MIA, affecting the fetal brain development and offspring behaviour. The a7nAChR suppresses inflammatory response in the fetal brain by inhibiting interleukin (IL) 6 production and, consequentially, the loss of Chrna7 in the offspring increases their vulnerability to MIA-induced autistic and SZ-like symptoms. Maternal choline supplementation triggers an anti-inflammatory response in the fetal brain and thus decreases the MIA-induced IL-6 elevation during embryonic stage and the autistic and SZ-like behaviours in the adults. 87 Whole-exome sequencing (WES) data combined with a statistical method designed to identify the responsible gene(s) within Individuals carrying a homozygous microdeletion spanning FAN1 show severe neurodevelopmental abnormalities, including microcephaly. 89 It is likely that deleterious FAN1 mutations increase risk for SZ and ASD by interfering with aspects of early neuronal development, namely proliferation. 
16p11.2 rearrangements
The 593-Kb proximal deletions and duplications at 16p11.2 (figure 4), although observed in individuals with normal phenotypes, 90 have been associated with a broad range of NDs (table 5) . A detailed phenotypical analysis of the 16p11.2 CNV has shown the existence of partially mirroring phenotypes: the deletion is associated with ASD, ID, behavioural disorders, CAs, diabetes-independent obesity and macrocephaly, while the reciprocal duplication is associated with autism and SZ, anorexia and microcephaly. 41 91-95 Jacquemont and colleagues have thus speculated that head circumference and neuronal circuitry abnormalities could be linked to cognitive function and energy balance impairments in patients with 16p11.2 rearrangements, and so the abnormal food intake could be a direct result of a particular ND. 95 Conceptually, this would make us add obesity to the list of CNV-associated NDs, an intriguing shift to the field, but one that fits the increasing knowledge on the biology of food intake and metabolism regulation by the CNS.
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KCTD13 is one of the 29 annotated genes within this CNV, among some transcription factors (eg, MAZ, TBX6), chromatin 161 ).
cerebral cortex of mouse models with duplication/deletion and cell lines derived from multiplex ASD families with the CNV showed that expression of all genes in the CNV region correlated well with their DNA copy number. Effects of 16p11.2 rearrangements on gene expression outside the CNV region were also observed, including apparent positional effects in cis and in trans and dysregulation of genes located in other chromosomal regions. In conclusion, alteration of 16p11.2 genes seems to disrupt expression networks that involve other genes and pathways known to contribute to ASD.
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The 220-kb 16p11.2 distal deletion (28.73-28.95 Mb) was first described in association with severe early onset obesity alone. 99 Soon after, it was also described in patients with DD, ID and other variable phenotypical features in addition to obesity 12 44 and, more recently, in association with SZ (table 6) . 31 43 The minimal deleted region contains nine genes, several of which are implicated in neurological diseases (TUFM, ATP2A1), immunity and glucose homoeostasis. The most likely obesity candidate gene was postulated to be SH2B1, involved in leptin and insulin signalling, 100 and implicated in the regulation of body weight and glucose homoeostasis in mice. 101 
16p13.11 rearrangements
Common features of the patients with the 1.5 Mb deletions at 16p13.11 (16p13.11del) include ID, microcephaly and epilepsy, while patients carrying the reciprocal duplication have pronounced behavioural problems in addition to ID and/or CAs. 45 102 A threefold excess of duplications and deletions has been observed in SZ cases (table 7) , 31 46 and both rearrangements have been implicated in ADHD. 48 103 The 16p13.11del is significantly associated with GGE 33 67 104 and appears to be the most prevalent single genetic risk factor for overall seizure susceptibility (0.6% of patients with epilepsy). 47 The 16p13.11 consensus region spans seven genes (MPV17L, C16orf45, KIAA0430, NDE1, MYH11, C16orf63, ABCC1) (figure 4). 48 103 Among them, the nuclear distribution gene E homologue 1 (NDE1) is of particular interest, because the nudE neurodevelopment protein 1 is essential for mitosis and neurodevelopment, and interacts with the disrupted in SZ 1 protein, 105 implicated in SZ and in other major psychiatric disorders.
106-108 NDE1 deficiency impairs neurogenesis, by causing profound neuronal proliferation defects and a deficiency in cortical lamination, as observed in Nde1-null mice and in patients with NDE1 homozygous mutations, who present extreme microcephaly with lissencephaly. 106 107 Severe microcephaly, including fetal brain disruption, can also be caused by the combination of a 16p13.11del and a mutation on the nondeleted NDE1 homologue. 108 As the 16p13.11 region includes other genes expressed during brain development, such as ABCC1, NOMO1, NTAN1, PDXDC1, it has been suggested that sequencing these candidate genes for second-hit mutations in patients with 16p13.11del and severe neurodevelopmental phenotypes could give new insights into these disorders. 
22q11.2 rearrangements
DiGeorge syndrome, velocardiofacial syndrome or 22q11.2 deletion syndrome (22q11DS) results from 1.5-3 Mb heterozygous microdeletions on 22q11.2 locus; these deletions (22q11.2del) represent one of the most common disease-causing CNVs. The associated phenotype is variable but frequently includes cleft palate, hypocalcaemia, cardiac defects, immune dysfunction and neuropsychiatric illness. [109] [110] [111] About 85% of patients with 22q11DS have the 3 Mb deletion (∼60 genes), while the remainder have the smaller 1.5 Mb deletion (28 genes), or atypical deletions, containing a small number of genes (figure 5). 111 Patients with 22q11DS have variable psychiatric and cognitive presentations: children have a high prevalence of ASD, ADHD, anxiety disorders and psychotic features 112 while up to 30% of adolescents and adults develop SZ or affective psychosis. 113 114 The 22q11.2del was the first CNV implicated in SZ 115 and is now considered one of the greatest known risk factors for psychotic illness, accounting for up to 1-2% of sporadic cases of SZ (table 8) . 30 31 111 114 The reciprocal 3 Mb duplication is usually associated with milder and more variable phenotypes: DD, speech delay and cognitive deficits have been reported in 50-80% of the patients, but asymptomatic carriers were also observed (table 7) . 42 109 116-119 Data from genetic association studies in human patients and control subjects, indicate that a substantial number of genes are likely to contribute to 22q11DS key phenotypes. 120 The TBX1 gene, although responsible for some major aspects of the phenotype of 22q11.2DS (abnormal facies, cardiac defects, thymic hypoplasia, velopharyngeal insufficiency of the cleft palate and parathyroid dysfunction with hypocalcaemia), does not seem to be responsible for the cognitive/neuropsychiatric features commonly seen in patients with 22q11DS. 121 Two other genes within this CNV are COMT and PRODH. The COMT gene encodes a postsynaptic enzyme that modulates dopaminergic clearance 122 and, given the association between dopamine deficits and several psychiatric disorders such as SZ and ADHD, 123 has been widely investigated. The functional polymorphism Val158Met (rs4680) affects enzyme activity and dopamine availability in brain areas where this neurotransmitter is released, such as the prefrontal cortex. The high-activity COMT 158 Val allele has, therefore, been suggested as a small but reliable risk factor for SZ, at least for people of European ancestry. 124 The PRODH gene encodes the enzyme that converts proline to glutamate in mitochondria, dysfunction of which has been linked to the development of psychiatric illness, including SZ. 125 There is also evidence for epistatic interaction between COMT and PRODH: Prodh-deficient mice show Comt upregulation in prefrontal cortex, which likely represent a homoeostatic response to enhanced dopaminergic signalling resulting from Prodh deficiency, 126 and elevated plasma proline levels. 127 If COMT upregulation is indeed one of the mechanisms used to control cortical dopaminergic hypersensitivity, then most patients with 22q11DS who are haploinsufficient for both genes, particularly those who have the low-activity COMT 158 Met allele, may be at a particular disadvantage because they are unable to compensate efficiently, through COMT, for the cortical dopaminergic hyperactivity induced by PRODH deficiency. 114 126 127 Based on human and mouse model studies of 22q11.2 rare CNVs, Hiroi proposed that alterations of a distinct set of multiple, non-contiguous genes encoded in this chromosomal region, together with environmental factors and modulatory impacts of the genetic background, could variably shift the probabilities of phenotypes along a predetermined developmental trajectory. 128 
IMPACT OF CNVS
The predictive value of genetic variants depends, in part, on their penetrance, defined as the probability of an individual with a certain genotype to present a phenotype at all, whereas the concept of variable expressivity pertains to the variability in the spectrum of symptoms/phenotype.
Vassos and colleagues estimated the penetrance of CNVs associated with SZ, at 15q13.3, 1q21.1, 15q11.2, 17p12, 2p16.3, 16p13.1 and 16p11.2 and concluded that the highest penetrance was observed for 15q13.3del (6-9%) and the lowest for 15q11.2del (2%). 129 Calculation of the frequencies of 70 implicated CNVs in patients, controls and the general population led to the conclusion that, except for 16p11.2dup, 3q29del, 16p13.11dup and the smaller 15q13.3 (CHRNA7) duplications, the penetrance of CNVs is higher for the development of a disorder from the group of DD/ASD/CAs than for SZ. This observation has also strengthened the evidence of a genetic overlap, at least for some CNVS, among DD, ASD and SZ; some CNVs are so highly pathogenic and penetrant that they cause earlier-onset disorders, such as DD/ASD/CAs, precluding the diagnosis of SZ. 130 
Studying the functional impact of CNVs and the neurobiology of NDs
The identification of this unexpectedly abundant type of genetic variation and the increasingly clear role of CNVs in NDs has led to the need to develop appropriate models for the study of disease pathogenesis, aiming at the development of therapeutic strategies for these diseases.
Despite the difficulty of modelling all aspects of human psychiatric and neurodevelopmental phenotypes in animals (eg, hallucinations and delusions characteristic of SZ, hard to characterise in other species), animal models may contribute to the elucidation of brain anatomy, functional connectivity, cognitive and behavioural features, and also molecular mechanisms that reflect aspects of human phenotypes. 131 Among the most used are mouse models, which can be engineered in several ways: some express multiple genes within the human chromosomal region that is being studied; others have the syntenic region deleted or duplicated; finally, there are individual gene knockout or overexpression models which allow us to dissect the contribution of a particular gene to a given phenotype. 131 132 Other models, like zebra fish or Caenorhabditis elegans, are also used particularly to assess the function of particular genes. 133 134 More recently, the possibility of using human induced pluripotent stem cells (hiPSCs) has opened a wide range of experiment possibilities, including in drug screening. 135 
Animal models
Animal models of CNV-related neurodevelopmental impairment are not very numerous but some interesting examples exist that illustrate the possibilities in this field.
Haploinsufficieny of Cyfip1, believed to be one of the key aspects of the 15q11.2 (BP1-BP2) deletions, produces fragile-X-like phenotypes in mice, which is consistent with a role for the interaction of Cyfip1 and Fmrp in regulating activity-dependent translation in neurons. 136 A 15q13.3 microdeletion mouse model (Df(h15q13)/_), generated by hemizygous deletion of the orthologous region, displays key phenotypes including SZ, epilepsy and aggression, all associated with the human syndrome. 137 Mice with deletion (as well as reciprocal duplication) of the chromosomal region corresponding to the human 16p11.2 locus, have provided functional evidence that 16p11.2-CNVs cause brain and behavioural anomalies. Notably, the macrocephaly (with deletion) and microcephaly (with duplication) observed in human subjects were replicated in mice. Regarding behaviour, 16p11.2del mice showed hyperactivity, difficulty adapting to change, sleeping abnormalities, and repetitive or restricted behaviours, while 16p11.2dup animals were hypoactive. 138 Half of the 16p11.2del mice died postnatally, suggesting a potential link between 16p11.2-CNVs and infant mortality, that remains to be explored in humans; those that survived to adulthood were healthy and fertile, but exhibited behaviour changes characteristic of rodents with lateral hypothalamic and nigrostriatal lesions. 138 Consistently with human postmortem studies showing that neuronal migration abnormalities in the cerebral cortex are a feature of 22qDS, 139 diminished dosage of 22q11 genes disrupts neurogenesis and cortical development in mice. 140 The 22q11.2del disrupts an established molecular mechanismCxcr4-mediated signalling-that regulates cortical interneuron migration and placement. 141 Deficits of various degrees across hippocampus and alterations in synaptic plasticity and structural connectivity within the prefrontal cortex, thought to be contributors to the 22q11.2-related cognitive and psychiatric impairments, were shown to occur in other 22q11.2del mouse models. 142 143 Altered brain microRNAs and abnormalities in the formation of neuronal dendrites and spines, including those in corticocerebellar, corticostriatal and corticolimbic circuits were also observed in these models. 144 145 Future studies with these mouse models should allow an increased understanding of pathogenic processes underlying NDs as well as the design and testing of suitable therapeutic strategies for these disorders.
Human induced pluripotent stem cells
hiPSCs are adult pluripotent stem cells generated from somatic cells that can be derived from adult humans, and represent a potentially limitless source of human cells to study disease: hiPSCs also make possible the study of human neurons, a previously inaccessible cell type, carrying the genetic information from patients with a specific mutation or a neuropsychiatric disease. 146 Patient-derived cells (eg, dermal fibroblasts from a skin biopsy or peripheral blood mononuclear cells) can be reprogrammed into iPSCs by forced expression of four pluripotency-associated transcription factors: OCT4, SOX2, KLF4 and c-MYC. These cells are similar to human embryonic stem cells in morphology, proliferation, surface antigens, gene expression, epigenetic status of pluripotent cell-specific genes and telomerase activity. 147 Although there are no publications to date describing the CNVs described here, hiPSCs have been used to model NDs that include autistic features: neurons differentiated from hiPSCs of affected individuals or from genetically modified hiPSCs exhibited disease-related phenotypes, such as fewer synapses, smaller soma size, deficits in calcium signalling and in spontaneous excitatory synaptic communication, when compared with unaffected control neurons. 148 hiPSC-derived neurons in patients with SZ showed an aberrant migration, increased oxidative stress, 149 significantly reduced neuronal connectivity, reduced neurite outgrowth, reduced dendritic levels of PSD95 and altered gene expression profiles; interestingly, key cellular and molecular elements of the SZ phenotype were ameliorated following treatment of SZ hiPSC neurons with the antipsychotic loxapine. 150 The limitations of hiPSC-based approaches for studying psychiatric disease are mainly neuron-to-neuron variability, hiPSC-to-hiPSC variability and patient-to-patient variability and, therefore, hiPSC-based studies will not replace MRI, postmortem and genetic studies of patients with psychiatric disorders. 151 Nevertheless, the development of these models opens new avenues for the deeper understanding of pathogenic mechanisms and-importantly-for the development of new therapeutic strategies for these disorders, by means of large-scale screening of chemical libraries with disease-specific hiPSCs. 135 
TRANSLATION OF THE RECENT KNOWLEDGE TO THE CLINICAL CONTEXT-GENETIC COUNSELLING
Until recently, counselling of a patient/family with history of neuropsychiatric disease too often meant discussion of empirical risks since in the majority of cases the aetiology was not known. A good deal of the counselling session would be dedicated to clearly transmitting the value and limitations of these empirical risks and what this would translate into in the patient's and his/ her relatives' life. In this context, unburdening the patient, parents and extended family from stigma and guilt was-and still is-paramount.
The technological advances in molecular genetics in the last decade-namely CMA and WES-have, however, revolutionised the field of medical genetics regarding diagnostic yield.
As a matter of fact, the 15-20% diagnostic yield of CMA led multiple medical entities (such as the American College of Medical Genetics, American Academy of Neurology and the American Academy of Pediatrics) to recommend microarray as a first-tier clinical diagnostic test for individuals with ASD, ID/DD or multiple CAs. 152 This contributed to: (A) a better understanding of the entire spectrum of fully penetrant genes and regions that cause syndromic NDs, the current understanding being that the spectrum fades into non-syndromic mild ID and ASD; (B) detection of CNVs that are significantly enriched in cases but also present in controls. In fact, the highly increased risk of developing neurodevelopmental phenotypes associated with some of these CNVs makes them an unavoidable element in the clinical context in paediatrics, neurology and psychiatry and should be addressed by a multidisciplinary clinical team, ideally including a geneticist.
Both scenarios are challenging in terms of counselling. In the case of a child with a significant disability (in the context of syndromic or non-syndromic disease) due to a de novo CNV with complete penetrance, genetic counselling has straightforward medical benefits such as a tailored follow-up for the child, accurate genetic counselling for the family and the possibility of prenatal diagnosis. Much greater challenge is faced when counselling for a recurrent CNV with known incomplete penetrance and/or variable expressivity, or when there is a degree of uncertainty on whether the CNV indeed poses risk for health: in this case, the translation of this recent knowledge into clinical practice has not been trivial. Even though it may be tempting to postpone its use in the clinical context-until more solid data or guidelines are developed-the complexity of these findings should be embraced since some of these CNVs present ORs above 5 that have been replicated in independent studies. Interestingly, risk factors for cancer development or cardiovascular disease frequently have lower multivariate-adjusted ORs and yet they are heavily used in a patient's clinical management. This is because many of these risk factors are preventable (eg, obesity) or help us set a lower threshold for screening or intervention. But the same applies for ND, where early intervention (eg, stimulation and behavioural therapy) and identification of other factors that could contribute to developmental difficulties or arrest (eg, vision and hearing screening) should be considered.
Incomplete penetrance and variable expressivity
It is known that deletions and duplications of the same locus can present with identical and mirror features. Also, in general, the penetrance of deletions is higher than that of duplications. For example, 16p11.2del are more penetrant and more frequently de novo events than duplications. 153 In addition to incomplete penetrance, many CNVs also present variable expressivity. For example, the 15q13.3del may be detected in individuals who are ascertained with different NDs such as ID, SZ and BD. This may be viewed as interfamilial variability. However, this can also translate into intrafamilial variability in a scenario where, for example, a child with ASD has an apparently healthy mother and maternal relatives with SZ and BD. The recognition of the incomplete penetrance and the variable expressivity is needed in order to assemble the relevant information for counselling.
Penetrance and variable expressivity might be influenced by other genetic, epigenetic and environmental factors. Different risk elements might contribute to the preferential development of one neurophenotype over another, as well as determine severity. Different models to explain variable expressivity have been suggested: additive (two co-occurring CNVs affecting independent functional modules/pathways) and epistatic (two CNVs affecting the same functional module/pathway). 154 The study of more than 20 000 cases and around 14 500 controls offered evidence for the additive model in the case of 16p12.1del. 155 
Carriers, controls and general population
Neuropsychiatric profiling of patients with 22q11.2del has shown that these patients present a wide IQ range, from normal to moderate ID (ie, −3SD below the mean. 156 A similar study design was used to evaluate patients with 16p11.2del, which showed that individuals with the deletion had an average IQ 1 SD below the population mean). However, when compared with relatives without the deletion, individuals with the 16p11.2 deletion had a 1.8 standard deviation loss. 157 Two conclusions can be inferred: (1) the very same damaging CNV might impact differently in different individuals, depending on their genetic background; (2) one may be able to predict the phenotypical severity of an individual with a deleterious CNV by using parents as proxies. This knowledge could be useful in postnatal diagnosis, for tailored follow-up and early intervention, and in prenatal care. 158 Complementary, detailed study of carriers of neuropsychiatric CNVs revealed that they show cognitive abilities and brain structure changes situated between those of controls (ie, without a neuropsychiatric CNV) and patients with NDs, even though they often did not fulfil criteria for ASD, ID or SZ. 159 One could speculate that what is sometimes perceived as lack of penetrance is actually variable expressivity, which could be detectable provided more granular phenotyping had been performed.
Prenatal diagnosis
Counselling in a prenatal diagnosis setting is a particularly delicate task. This is true in the case of a de novo fully penetrant pathogenic CNV, but even more so for CNVs with incomplete penetrance and variable expressivity or for variants of uncertain significance. The latter is a rare event (about 1%) 160 but a source of great anxiety and request of multiple/serial complementary exams in the hope of shedding some light on the decisions need to be made within a narrow timeframe.
Parental testing can bring some solace when it is shown that the variant is inherited, or escalating of anxiety if it is shown to be de novo. And yet, inheritance of a variant from a healthy parent is no guarantee of it being benign-and the other way around. In case one of the parents is a carrier of a CNV with incomplete penetrance, additional attention should be devoted to not stigmatise the parent or distort the couple dynamics.
Rosenfeld and colleagues calculated empirical risks taking into account frequencies of 13 recurrent CNVs in cases and controls and confirmed an already known point: deletions are usually more penetrant events than the reciprocal duplications. The associated risk of an abnormal phenotype for distal 1q21.1del is ∼37% versus ∼29% for duplications; ∼62.4% for distal 16p11.2del versus 11.2% for duplications; 46.8% for proximal 16p11.2del versus 27.2% for duplications. The risk associated with 16p13.11del is 13.1%; the risk associated with 22q11.2dup is 21.9%, 35 whereas the risk associated with the reciprocal deletion is ∼55%, at least for SZ. 129 This is useful A broad phenotypical spectrum, ranging from normal development, to cognitive impairment, is associated with these rearrangements. 4. Genetic and environmental additional events are likely necessary to push the neuropsychiatric phenotype beyond threshold of disease. 5. Counselling for a CNV poses a great challenge, due to the variability on penetrance and expressivity and to the uncertainty on whether a given CNV poses risk for health.
information as a ∼10% risk of neurodevelopmental problems associated with a 15q11.2 deletion is more reassuring than the ∼50% risk associated with a 16p11.2 proximal deletion. 35 Still, these numbers should be approached cautiously and take into account family history, pregnancy history, parental resilience, capability of accepting increased risk, religious beliefs, ethical orientations and socioeconomical network of support (boxes 1-3).
Care should be taken to avoid psychological harm to carriers (feelings of blame and low self-esteem) and their families (discrimination of an entire branch or community). Multiple counselling sessions with several relatives are needed to evaluate who is at risk and to reinforce the meaning of arid statistical concepts. When emotional stress overpowers reasoning, psychotherapeutic follow-up may be beneficial.
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Box 3 Future perspectives 1. Further gene expression assays (either using lymphoblastoid cell lines or postmortem brain samples) are necessary to address the impact of CNVs in dosage-sensitive gene expression in normal brain development. 2. Functional analysis using animal models and/or human induced pluripotent stem cells (hiPSCs) are important for the deeper understanding of pathogenic mechanisms and for the development of new therapeutic strategies. 3. The complete characterisation (including genetic and environmental aspects) of: (A) large groups of patients with a given CNV and; (B) large cohorts of control individuals carrying the same CNV, will hopefully give some insights concerning the additional events necessary to push the neuropsychiatric phenotype beyond threshold of disease. 4. As the Encyclopedia of DNA Elements (ENCODE) project moves forward, different genome elements, including 'non-coding' sections of the genome, will be better defined, characterised and integrated in order to assess their roles in human biology and disease.
